Real time imaging of biomarkers in the parkinson's brain using mini-implantable biosensors. II. pharmaceutical therapy with bromocriptine

Pharmaceuticals

Volumn 2, Issue 3, 2009, Pages 236-249

  Broderick, Patricia A ^a,b,c   Kolodny, Edwin H ^c  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; Biomarkers; Biosensors; Brain; Dopamine; Dorsal striatum; Dynorphin A; Electrochemistry; Monoamines; Movement disorders; Neuromolecular imaging; Neurons; Neurotransmitters; Nigrostriatal pathways; Parkinson s disease; Peptides; Serotonin; Somatostatin; Substantia nigra

Indexed keywords

EID: 80055081772     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph2030236     Document Type: Article

References (31)

1. Matthias, C.J. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin. Auton. Res. 2008, 18(Suppl. 1), 25–29.
2. Matuja, W.B.; Aris, E.A. Motor and non-motor features of Parkinson’s disease. E. Afr. Med. J. 2008, 85, 3–9.
3. Broderick, P.A. Distinguishing in vitro electrochemical signatures for norepinephrine and dopamine. Neurosci. Lett. 1988, 95, 275–280.
4. Broderick, P.A. Cathodic Electrochemical Current Arrangement with Telemetric Application. U.S. Patent 4, 883,057, 1989.
5. Broderick, P.A. Characterizing stearate probes in vitro for the electrochemical detection of dopamine and serotonin. Brain Res. 1989, 495, 115–121.
6. Broderick, P.A. Microelectrodes and their use in cathodic electrochemical current arrangement with telemetric application. U.S. Pat. 5,433,710, 1995.
7. Broderick, P.A. Microelectrodes and their use in an electrochemical arrangement with telemetric application. U.S. Pat. 5, 938, 903, 1999.
8. Broderick, P.A.; Pacia, S.V.; Doyle, W.K.; Devinsky, O. Monoamine neurotransmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 2000, 878, 49–63.
9. Broderick, P.A.; Pacia, S.V. Imaging white matter signals in epilepsy patients: A unique sensor technology. In Bioimaging in Neurodegeneration; Broderick, P.A., Rahni, D.N., Kolodny, E.H., Eds.; Humana Press Inc., Springer: Totowa, NJ, USA, 2005; pp. 199–206.
10. Broderick, P.A.; Pacia, S.V. Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors and brain and spinal cord injuries using microelectrodes with microvoltammetry. U.S. Pat. 7,112,319 2006, Continuation in Part, 2009, Pending.
11. Broderick, P.A. Studies of oxidative stress mechanism using a morphine/ascorbate animal model and novel N-stearoyl cerebroside and laurate sensors. J. Neural Transm. 2008, 115, 7–17.
12. Broderick, P.A.; Ho, H.; Wat, K.; Murthy, V. Laurate biosensors image brain neurotransmitters in vivo: Can an antihypertensive medication alter psychostimulant behavior? Sensors 2008, 8, 4033– 4061.
13. Broderick, P.A. In vivo voltammetric studies on release mechanisms for cocaine with gamma-butyrolactone. Pharmacol. Biochem. Behav. 1991, 40, 969–975.
14. Broderick, P.A.; Ho, H,; Li, Y-S; Kolodny, E.H. Lovenox® affects striatal neurotransmitters on line with laser Doppler flowmetry: Neuromolecular imaging (NMI) in an animal model of acute ischemic stroke. Oral Presentation in Society for Neuroscence, Chicago, IL, USA, 18 October, 2009.
15. Haile, M.M.; Broderick, P.A.; Li, Y.-S.; Quartermain, D.; Blanck, T.J.J.; Bekker, A.Y. Nimodipine reverses the hypoxia-induced elevation of dopamine and serotonin in striatum of adult rats. Poster Presentation at American Society of Anesthesiologists, Orlando, FL, USA, 17 October 2008.
16. Haile, M.M.; Broderick, P.A.; Li, Y.-S.; Quartermain, D.; Blanck, J.J.; Bekker, A.Y. Nimodipine reverses the hypoxic elevation of tryptophan and serotonin in the striatum of adult rats. Poster Presentation at the International Anesthesia Research Society, San Diego, CA, USA, March 13–17, 2009.
17. Hoffman, R.M.; Yang, M. Whole-body imaging with fluorescent proteins Nat. Protoc. 1 2006, 1429–1438.
18. Hoffman, R.M. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat. Rev. Cancer 2006, 5, 796–866.
19. Hasegawa, S.; Yang, M.; Chishima, T.; Miyagi, Y.; Shimada, H.; Moossa, A.R.; Hoffman, R.M. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. Cancer Gene Ther. 2000, 7, 1336–1340.
20. Castano, A. P.; Liu, Q.; Hamblin, M. R. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Br. J. Cancer 2006, 94, 391–397.
21. Wack, S.; Hajri, A.; Heisel, F.; Sowinska, M.; Berger, C.; Whelan, M.; Marescaux, J.; Aprahamian, M. Feasibility, Sensitivity, and Reliability of Laser-Induced Fluorescence Imaging of Green Fluorescent Protein-expressing Tumors in vivo. Mol. Ther. 2003, 7, 765–773.
22. Broderick, P.A.; Doyle, W.K.; Pacia S.V.; Kuzniecky, R.I.; Devinsky, O.; Kolodny, E.H. A clinical trial of an advanced diagnostic biomedical device for epilepsy patients. J. Long-Term Eff. Med. Implants. 2009, 18, 50.
23. Broderick, P.A.; Doyle, W.K.; Pacia S.V.; Kuzniecky, R.I.; Devinsky, O.; Kolodny, E.H. Intra-operative Neuromolecular (NMI) in neocortex of epilepsy patients: Comparison with resected neocortical epileptogenic tissue. Poster Presentation at The American Epilepsy Society, Boston, MA, USA, December 4–8, 2009.
24. Pellegrino, L.J.; Pellegrino, A.S.; Cushman, A.J. A Stereotaxic Atlas of the Rat Brain, Plenum Press: New York, NY, USA, 1979.
25. Henry, B.; Brotchie, J.M. Potential of opioid antagonists in the treatment of levo-dopa-induced dyskinesias in Parkinson’s Disease. Drugs Aging 1996, 9, 149–158.
26. Hely, M.A.; Morris, J.G.; Reid, W.G.; O'Sullivan, D.J.; Williamson, P.M.; Rail, D.; Broe, G.A.; Margrie, S. The Sydney Multicentre Study of Parkinson’s disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodsopa-carbidopa. J. Neuro. Neurosurg. Psychiatry 1994, 57, 903–910.
27. Montastruc, J.L.; Rascol, O.; Senard, J.M.; Rascol, A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J. Neuro. Neurosurg. Psychiatry 1994, 57, 1034–1038.
28. Brannan, T.; Martinez-Tica, J.; DiRocco, A.; Yahr, M.D. Low and high dose bromocriptine have different effects on striatal dopamine release: An in vivo study. J. Neural Transm. 1993, 6, 81–87.
29. Jackson, D.M.; Mohell, N.; Georgiev, J.; Bengtsson, A.; Larsson, L.G.; Magnusson, O.; Ross, S.B. Time course of bromocriptine induced excitation in the rat: Behavioral and biochemical studies. Naunyn Schmiedebergs Arch. Pharmacol. 1995, 351, 146–155.
30. 30, Wang, Z.H.; Ji, Y.; Shan, W.; Zeng, B.; Raksadawan, N.; Pastores, G.M.; Wisnewski, T.; Kolodny, E.H. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat mouse model of Parkinson’s disease. Neuroscience 2002, 113, 629–640.
31. Lu, J.Q.; Stoessel, A.J. Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Neuroscience 2002, 112, 261–266.